2011-09-28 – Page 3 – China Stock Advice

CO [Chinard Bloodrp] 20-F: FORM 20-F OR x For the fiscal year

[FORM 20-F OR x For the fiscal year ended March 31, 2011. OR ORte of event requiring this shellmpany report: For the transition period from ________ to ________ Chinard Bloodrporationyman Islands (Jurisdiction oforporation or organization) 48th Floor, Bank of China Tower 1 Garden Road Central, Hong KongR.] [Summary of Loanreementreement #[ ] Party A (Borrower): Beijing Jiachenhong Biological Technologies, Party B (Lender): Huaxia Bank, Beijing Xiushui Branch Article 1 Type of Loan WorkingpitalLoan Article 2 Amount and Currency of Loan 2.1 The currency of the loan stipulated in thereement is Renminbi (RMB).] [CordLife (Hong Kong) and Chinard Bloodrporation Marketingllaborationreement This Marketingllaborationreement (Agreement) isted theteecified on the execution page of thisreement.rdLife (Hong Kong) (CordLife HK), 31006823 AND Chinard Bloodrporation ("CCBC"), WHEREAS A.rdLife HK offers services ofrd blood stem cellllection, processing, testing and storage services to citizens of China giving birth in Hong Kong and their new born baby] [List of Subsidiaries Name Jurisdiction Chinard Blood Servicesrporationyman Islands China Stem Cellss Limitedyman Islands Beijing Jiachenhong Biological Technologies Limited Peoples Republic of China China Stem Cells (South)mpany Limited British Virgin Islands Guangzhou Municipality Tianhe Nuoya Bio-engineering Peoples Republic of China China Stem Cells (East)mpany Limited] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of Chinard Bloodrporation; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [Certification I,bert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of Chinard Bloodrporation; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [Certification CHINARD BLOODRPORATION September 28, 2011 Ting Zheng Chief Executive Officer September 28, 2011bert Chen Chief Financial Officer (Principal Financial and Accounting Officer) v233979_ex13-1.htm 7 EX-13.1] [Consent of Independent Registered Public Accounting Firm The Board of Directors Chinard Bloodrporation: Our reportted September 27, 2011 on thensolidated financial statementsntains an explanatory paragraph that states thempanympleted a share exchange with Chinard Blood Servicesrporation (CCBS) on June 30, 2009 and the share exchange has been accounted for financial reporting purposes the issuance of securities]

By info| 2016-02-04T17:46:02+00:00 September 28th, 2011|Categories: Chinese Stocks, CO, Webplus ver|Tags: 0001467808, 20-F, 2011-09-28, 6770, BLANK CHECKS, CO|0 Comments

CCCL [China Ceramics] 6-K: (Original Filing)

[China Ceramics Co., Ltd. c/o Stuart Management Co. 830 Post Road East Suite 205 Westport, CT 06880 USA Tel: 203-226-6288 Fax: 203-226-8022 September 28, 2011 James D. Dunning, Jr. 2 Sutton Place South Apt 17D New York, NY 10022 Alan G. Hassenfeld The Owen Building 101 Dyer Street Suite 401 Providence, RI 02903 Knott Partners 485 Underhill Boulevard Suite 205] [Copy of correspondence to: Stuart Management Company 830 Post Road East Suite 205 Westport, CT 06880 x Form 20-F ¨ Form 40-F ¨ ¨ ¨ Yes x No 1 99.1]

By info| 2016-03-21T18:56:20+00:00 September 28th, 2011|Categories: CCCL, Chinese Stocks, SEC Original|Tags: 0001470683, 2011-09-28, 3250, 6-K, CCCL, STRUCTURAL CLAY PRODUCTS|0 Comments

CCCL [China Ceramics] 6-K: China Ceramics Co., Ltd. c/o Stuart Management Co.

[China Ceramics Co., Ltd. c/o Stuart Management Co. 830 Post Road East Suite 205 Westport, CT 06880 USA Tel: 203-226-6288 Fax: 203-226-8022 September 28, 2011 James D. Dunning, Jr. 2 Sutton Place South Apt 17D New York, NY 10022 Alan G. Hassenfeld The Owen Building 101 Dyer Street Suite 401 Providence, RI 02903 Knott Partners 485 Underhill Boulevard Suite 205] [Copy of correspondence to: Stuart Management Company 830 Post Road East Suite 205 Westport, CT 06880 x Form 20-F ¨ Form 40-F ¨ ¨ ¨ Yes x No 1 99.1]

By info| 2016-03-21T18:57:25+00:00 September 28th, 2011|Categories: CCCL, Chinese Stocks, Webplus ver|Tags: 0001470683, 2011-09-28, 3250, 6-K, CCCL, STRUCTURAL CLAY PRODUCTS|0 Comments

CXDC [China XD Plastics Co] 8-K: (Original Filing)

[CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF SERIES D JUNIOR CONVERTIBLE PREFERRED STOCK OF CHINA XD PLASTICS COMPANY LIMITED Board of Directors Company Articles of Incorporation Preferred Stock Designation and Amount Series D Preferred Stock Ranking Senior Stock Common Stock pari passu Junior Stock Dividends and Distributions Voting Rights By-laws Two Directors Number Minimum Number Series D Director Series D] [China XD Plastics Announces Closing of $100 Million Equity Investment by Morgan Stanley Private Equity Asia - Board of Directors Expands from Seven to Nine - 28 HARBIN, CHINA, September Under the terms of the transaction, MSPEA has purchased redeemable convertible preferred shares of the Company that are convertible into common stock at an initial conversion price of US$6.25 per] [Item 3.03. Material Modification to Rights of Security Holders. Company Certificate of Designation Series D Preferred On September 28, 2011, China XD Plastics Company Limited (the “ Series B Preferred Series C Preferred Senior Preferred]

By info| 2016-03-25T16:41:40+00:00 September 28th, 2011|Categories: Chinese Stocks, CXDC, SEC Original|Tags: 0001353970, 2011-09-28, 3086, 8-K, CXDC, PLASTICS FOAM PRODUCTS|0 Comments

CXDC [China XD Plastics Co] 8-K: CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF SERIES

[CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF SERIES D JUNIOR CONVERTIBLE PREFERRED STOCK OF CHINA XD PLASTICS COMPANY LIMITED Board of Directors Company Articles of Incorporation Preferred Stock Designation and Amount Series D Preferred Stock Ranking Senior Stock Common Stock pari passu Junior Stock Dividends and Distributions Voting Rights By-laws Two Directors Number Minimum Number Series D Director Series D] [China XD Plastics Announces Closing of $100 Million Equity Investment by Morgan Stanley Private Equity Asia - Board of Directors Expands from Seven to Nine - 28 HARBIN, CHINA, September Under the terms of the transaction, MSPEA has purchased redeemable convertible preferred shares of the Company that are convertible into common stock at an initial conversion price of US$6.25 per] [Item 3.03. Material Modification to Rights of Security Holders. Company Certificate of Designation Series D Preferred On September 28, 2011, China XD Plastics Company Limited (the “ Series B Preferred Series C Preferred Senior Preferred]

By info| 2016-03-25T16:42:30+00:00 September 28th, 2011|Categories: Chinese Stocks, CXDC, Webplus ver|Tags: 0001353970, 2011-09-28, 3086, 8-K, CXDC, PLASTICS FOAM PRODUCTS|0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-K: (Original Filing)

[] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James J. Tong, certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer EX-32.1 4 ex32one.htm CERTIFICATON] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James J. Tong Chief Financial Officer EX-32.2 5 ex32two.htm CERTIFICATON]

By info| 2016-03-27T20:16:29+00:00 September 28th, 2011|Categories: Chinese Stocks, SEC Original, TPI|Tags: 0001362718, 10-K, 2011-09-28, 2834, PHARMACEUTICAL PREPARATIONS, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-K:

[] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James J. Tong, certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer EX-32.1 4 ex32one.htm CERTIFICATON] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James J. Tong Chief Financial Officer EX-32.2 5 ex32two.htm CERTIFICATON]

By info| 2016-03-27T20:17:18+00:00 September 28th, 2011|Categories: Chinese Stocks, TPI, Webplus ver|Tags: 0001362718, 10-K, 2011-09-28, 2834, PHARMACEUTICAL PREPARATIONS, TPI|0 Comments

CLNT [Cleantech Solutions International] 8-K: (Original Filing)

[Company Contact: Mr. Fernando Liu Chief Financial Officer Cleantech Solutions International, Inc. Tel: +86-137-6134-7367 fol@cleantechsolutionsinternational.com Email: www.cleantechsolutionsinternational.com Web: Investor Relations Contact: Ms. Elaine Ketchmere CCG Investor Relations Tel: +1-310-954-1345 elaine.ketchmere@ccgir.com Email: www.ccgirasia.com Web: Cleantech Solutions Announces Approval for One-for-Three Reverse Stock Split Wuxi, Jiangsu Province, China September 28, 2011 Cleantech Solutions Board approved the Companys]

By info| 2016-01-10T01:25:14+00:00 September 28th, 2011|Categories: Chinese Stocks, CLNT, SEC Original|Tags: 0000819926, 2011-09-28, 3550, 8-K, CLNT, SPECIAL INDUSTRY MACHINERY (NO METALWORKING MACHINERY)|0 Comments

NPD [China Nepstar Chain Drugstore] CORRESP: (Original Filing)

[VIA EDGAR September 28, 2011 Jim B. Rosenberg, Senior Assistant Chief Accountant Mary Mast, Senior Staff Accountant Tabatha Akins, Staff Accountant Division of Corporation Finance 100 F Street, N.E. Re: China Nepstar Chain Drugstore Ltd. Form 20-F for the fiscal year ended December 31, 2010 Filed April 20, 2011 File No. 001-33751 Dear Mr. Rosenberg, Ms. Mast and Ms. Akins:]

By info| 2016-03-07T05:11:17+00:00 September 28th, 2011|Categories: Chinese Stocks, NPD, SEC Original|Tags: 0001414850, 2011-09-28, 5912, CORRESP, NPD, RETAIL-DRUG STORES AND PROPRIETARY STORES|0 Comments